Exposure
|
Osteophyte progression events
|
Person-time [years]
|
Crude HR (95% CI)
|
Adjusted HR (95% CI)a
|
csDMARD
|
404
|
2883.3
|
Ref (1.00)
|
Ref (1.00)
|
bDMARD
|
77
|
400.3
|
1.56 (0.90–2.47)
|
1.74 (1.11–2.74)
|
TNFi
|
66
|
362.7
|
1.16 (0.90–1.48)
|
1.25 (0.97–1.62)
|
Non-TNFi
|
11
|
37.3
|
1.60 (1.01–2.53)
|
1.82 (1.15–2.87)
|
Combination
|
226
|
1424.9
|
0.96 (0.82–1.13)
|
1.02 (0.87–1.20)
|
TNFi
|
203
|
1321.9
|
0.98 (0.83–1.16)
|
1.06 (0.90–1.25)
|
Non-TNFi
|
23
|
103
|
1.08 (0.73–1.61)
|
1.16 (0.78–1.71)
|
Past-use
|
23
|
131.5
|
0.90 (0.61–1.35)
|
0.91 (0.61–1.36)
|
Never-use
|
18
|
337.5
|
0.40 (0.23–0.68)
|
0.41 (0.23–0.72)
|
Exposure
|
JSN progression events
|
Person-time [years]
|
Crude HR (95% CI)
|
Adjusted HR (95% CI)a
|
csDMARD
|
231
|
3239.2
|
Ref (1.00)
|
Ref (1.00)
|
bDMARD
|
51
|
458.1
|
1.80 (0.92–3.49)
|
1.38 (1.01–1.86)
|
TNFi
|
43
|
410.4
|
1.33 (0.97–1.82)
|
1.32 (0.95–1.83)
|
Non-TNFi
|
8
|
47.4
|
1.88 (0.96–3.66)
|
1.76 (0.89–3.46)
|
Combination
|
136
|
1636.7
|
0.98 (0.79–1.20)
|
1.04 (0.83–1.29)
|
TNFi
|
124
|
1531
|
1.02 (0.82–1.27)
|
1.03 (0.82–1.29)
|
Non-TNFi
|
12
|
105.8
|
1.15 (0.67–1.98)
|
1.12 (0.65–1.94)
|
Past-use
|
16
|
145.8
|
1.15 (0.72–1.83)
|
1.19 (0.74–1.92)
|
Never-use
|
15
|
343.6
|
0.71 (0.40–1.27)
|
0.83 (0.46–1.48)
|
Exposure
|
Sclerosis progression events
|
Person-time [years]
|
Crude HR (95% CI)
|
Adjusted HR (95% CI)a
|
csDMARD
|
160
|
3302.2
|
Ref (1.00)
|
Ref (1.00)
|
bDMARD
|
27
|
484.1
|
1.66 (0.77–3.57)
|
1.07 (0.72–1.60)
|
TNFi
|
22
|
432.3
|
0.95 (0.61–1.46)
|
0.97 (0.63–1.52)
|
Non-TNFi
|
5
|
51.8
|
1.67 (0.77–3.60)
|
1.89 (0.87–4.11)
|
Combination
|
84
|
1673.7
|
0.90 (0.69–1.17)
|
0.97 (0.74–1.27)
|
TNFi
|
75
|
1554.2
|
0.90 (0.69–1.18)
|
0.94 (0.71–1.24)
|
Non-TNFi
|
9
|
119.5
|
1.28 (0.67–2.45)
|
1.34 (0.71–2.52)
|
Past-use
|
10
|
159.5
|
1.02 (0.53–1.94)
|
1.04 (0.53–2.01)
|
Never-use
|
9
|
344.7
|
0.67 (0.34–1.35)
|
0.71 (0.35–1.45)
|
Exposure
|
Erosion progression
|
Person-time [years]
|
Crude HR (95% CI)
|
Adjusted HR (95% CI)a
|
csDMARD
|
41
|
3571.5
|
Ref (1.00)
|
Ref (1.00)
|
bDMARD
|
12
|
542.5
|
2.77 (0.79–9.70)
|
1.51 (0.76–3.00)
|
TNFi
|
9
|
481.1
|
1.46 (0.71–3.00)
|
1.32 (0.62–2.80)
|
Non-TNFi
|
NAb
|
NAb
|
NAb
|
NAb
|
Combination
|
19
|
1857.3
|
0.72 (0.42–1.25)
|
0.78 (0.43–1.40)
|
TNFi
|
17
|
1717.3
|
0.76 (0.43–1.34)
|
0.76 (0.41–1.39)
|
Non-TNFi
|
NAb
|
NAb
|
NAb
|
NAb
|
Past-use
|
6
|
182.7
|
2.35 (1.05–5.26)
|
2.40 (1.04–5.56)
|
Never-use
|
NAb
|
NAb
|
NAb
|
NAb
|
- bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence rate, HR hazard ratio, OA osteoarthritis, OR odds ratio, TNFi tumor necrosis factor inhibitor, JSN joint space narrowing
- aAdjusted for age, sex (time-invariant), body mass index, rheumatoid arthritis duration, rheumatoid factor (time-invariant), DAS28-esr score, prednisone use, cardiac disorders, hypertension, osteoporosis, hand surgery, large joint osteoarthritis, or hip/knee arthroplasty
- bNA: less than 5 outcomes not applicable for result estimation